List of Excipients in Branded Drug ORAQIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dentsply Pharmaceutical	ORAQIX	lidocaine and prilocaine	66312-110	HYDROCHLORIC ACID
Dentsply Pharmaceutical	ORAQIX	lidocaine and prilocaine	66312-110	POLOXAMER 188
Dentsply Pharmaceutical	ORAQIX	lidocaine and prilocaine	66312-110	POLOXAMER 407
Dentsply Pharmaceutical	ORAQIX	lidocaine and prilocaine	66312-110	WATER

# Oraqix Excipient Strategy and Commercial Opportunities in Dental Local Anesthesia

Last updated: August 4, 2026

Oraqix is a non-injectable periodontal gel containing lidocaine 25 mg/g and prilocaine 25 mg/g. Its commercial differentiation depends on the delivery system and excipient-controlled performance rather than on the active ingredients alone. The strongest development opportunities are generic or line-extension products that match the gel’s local retention, dosing convenience, single-use presentation, and periodontal indication while improving manufacturing cost, device usability, shelf life, or geographic access.

What is Oraqix and how does its formulation work?

Oraqix is indicated for local anesthesia in periodontal pockets during scaling and root planing in adults. It is applied directly into the periodontal pocket through a blunt applicator rather than administered by injection.

Attribute	Oraqix profile
Active ingredients	Lidocaine 25 mg/g and prilocaine 25 mg/g
Dosage form	Periodontal gel
Route	Local application into periodontal pockets
Primary use	Anesthesia during scaling and root planing
Standard container	Single-use 1.7 g cartridge
Maximum labeled treatment	Up to five cartridges per treatment session
Key excipients	Poloxamer 188, glycofurol, purified water, hydrochloric acid, sodium hydroxide
U.S. regulatory status	FDA-approved prescription product under NDA 021645
Commercial category	Dental local anesthetic and periodontal procedure product

The lidocaine-prilocaine combination is established in other topical anesthetic products, including EMLA. Oraqix differs through its periodontal delivery format and gel behavior. The formulation must enter narrow periodontal pockets, remain sufficiently localized during the procedure, release both anesthetics at a useful rate, and avoid excessive leakage into the oral cavity.

FDA labeling identifies the formulation excipients and dose limits. The product is not intended for injection or for use as a general-purpose topical oral anesthetic (FDA, 2003).

What excipients are used in Oraqix?

Oraqix uses a relatively compact excipient system:

Excipient	Likely formulation role
Poloxamer 188	Thermo-responsive or viscosity-modifying polymer, wetting aid, solubilization support
Glycofurol	Cosolvent for the active ingredients and formulation solvent
Purified water	Primary aqueous vehicle
Hydrochloric acid	pH adjustment
Sodium hydroxide	pH adjustment

The commercial value of this system is functional. The excipients support a gel that can be dispensed from a cartridge, pass through an applicator, distribute along the periodontal pocket, and retain sufficient contact time without requiring injection.

Why is poloxamer 188 commercially important?

Poloxamer 188 is a nonionic surfactant and polymeric excipient used in pharmaceutical formulations. In Oraqix, it can contribute to:

• Gel structure and rheology.
• Wetting of periodontal tissue.
• Dispersion and solubilization of lidocaine and prilocaine.
• Improved delivery through a narrow applicator.
• Local retention after application.

A substitute polymer could change viscosity, drug release, mucoadhesion, cartridge extrusion force, and the amount of product that remains in the periodontal pocket. These attributes are likely to be central to generic equivalence and product-line extensions.

What role does glycofurol play?

Glycofurol, also known as tetrahydrofurfuryl alcohol polyethylene glycol ether, is used as a pharmaceutical solvent or cosolvent. It can improve the solubility of lidocaine and prilocaine in the aqueous gel system.

A replacement with propylene glycol, polyethylene glycol, ethanol, or another cosolvent could affect:

• Drug solubility.
• Taste and oral tolerability.
• Local irritation.
• Drug release.
• Osmolality.
• Microbial control.
• Stability in the cartridge.

Because glycofurol is less common in consumer-facing oral products than some alternative solvents, a reformulation using a more familiar excipient could have a marketing benefit. It would require full compatibility and local-tolerance evaluation.

What formulation characteristics create commercial value?

Oraqix’s core formulation problem is a balance between fluidity and retention. A formulation that is too thin can leak from the pocket and reduce residence time. A formulation that is too viscous can increase applicator force, slow administration, or leave inconsistent doses.

The key critical quality attributes are likely to include:

1. Viscosity across the intended temperature range.
2. Extrusion force through the applicator.
3. Drug content uniformity.
4. Lidocaine and prilocaine release profiles.
5. pH and osmolality.
6. Cartridge fill weight.
7. Microbial quality.
8. Stability after storage.
9. Local tolerability.
10. Residual volume in the cartridge and applicator.

A competitor can pursue a Q1/Q2-equivalent formulation, meaning the same inactive ingredients qualitatively and quantitatively, or develop a differentiated formulation under a more complex regulatory route.

What formulation opportunities exist for Oraqix competitors?

Lower-cost generic formulation

The most direct opportunity is a generic product with the same active ingredients, dosage form, strength, route, and delivery method. The principal development risk is not active-ingredient chemistry. It is demonstrating that the product performs equivalently in the periodontal pocket.

A generic developer would need to control:

• Gel rheology.
• Drug release.
• Applicator performance.
• Cartridge dimensions and dose delivery.
• Stability and extractables.
• Local safety.
• Human factors for dental professionals.

An ANDA could be attractive if FDA accepts the product as pharmaceutically equivalent and therapeutically equivalent to Oraqix. If the delivery system or formulation differs materially, a 505(b)(2) strategy may be more appropriate.

Preservative-free or improved microbiological-control platform

Oraqix is supplied in a single-use cartridge, which supports a preservative-free commercial position. A new product could retain single-use packaging while improving microbial robustness through:

• Lower bioburden manufacturing.
• Improved container closure.
• Reduced residual air.
• Optimized fill-finish controls.
• A cartridge design with lower dead volume.

A multi-dose product could reduce packaging cost but would introduce greater microbial-control and dosing risks. It would also be less aligned with the existing product’s single-use presentation.

Extended-retention periodontal gel

A formulation with stronger mucoadhesion or slower drug release could seek differentiation through longer anesthesia or fewer applications. Possible excipient platforms include mucoadhesive polymers, cellulose derivatives, carbomers, polycarbophil, or thiolated polymers.

The commercial advantage would be meaningful only if the product reduces chair time, repeat application, or patient discomfort. Stronger adhesion can also increase removal difficulty, alter pocket measurements, or cause inconsistent dosing. The development program would need direct clinical evidence rather than relying only on in vitro release data.

Faster-onset formulation

A faster-onset product could compete with injection-based anesthesia for selected periodontal procedures. The formulation levers include:

• Particle size and drug solubilization.
• pH adjustment.
• Cosolvent selection.
• Polymer concentration.
• Drug-release modifiers.
• Improved pocket-contact behavior.

The main limitation is that rapid onset must be achieved without increasing systemic exposure or local irritation.

Improved taste and oral tolerability

Oraqix is applied in the oral cavity, where bitter taste, throat numbness, and unintended swallowing can reduce patient acceptance. A reformulated product could use taste-masking technology, lower leakage, or a modified delivery tip.

Flavoring agents and sweeteners would need careful assessment because they can affect pH, microbial stability, preservative strategy, and local tissue tolerance. Taste improvement is more commercially relevant for pediatric or anxious-patient applications, but those populations would require separate clinical and regulatory support.

What patents protect Oraqix and its excipient strategy?

The commercially defensible elements are likely to fall into four patent categories:

Patent category	Potential claim subject
Composition	Lidocaine-prilocaine concentrations and excipient ratios
Delivery system	Cartridge, applicator, blunt tip, dosing mechanism
Use	Periodontal application during scaling and root planing
Manufacturing	Mixing, filling, sterilization, and stability processes

For a generic entrant, the key distinction is between active patents, expired patents, unlisted patents, and patents that do not materially affect the proposed product. A formulation patent covering a narrow excipient ratio may create a design-around opportunity if the generic can preserve equivalent performance using a different polymer or solvent.

The U.S. product is an older FDA-approved product. The original regulatory exclusivity period is no longer a primary barrier to entry. Current market access is more likely to depend on formulation equivalence, device compatibility, manufacturing economics, and any enforceable patent claims than on regulatory exclusivity.

What is the Orange Book status of Oraqix?

Oraqix is associated with FDA NDA 021645. Orange Book analysis should distinguish:

• The NDA listing.
• Any currently listed patents.
• Patent-use codes.
• Expiration dates.
• Whether a listed patent covers the proposed generic product or only a specific method of use.

A Paragraph IV challenge would be relevant only if an unexpired Orange Book-listed patent covers the proposed ANDA product or its labeled use. A generic applicant could also submit a section viii statement and omit a patented method of use if the remaining label supports approval.

Because the principal product differentiation is its formulation and delivery system, a generic applicant should evaluate both composition claims and device-related intellectual property. A formulation that avoids a patented excipient ratio may still face device or method-of-use exposure.

When does Oraqix lose exclusivity?

Oraqix’s original FDA regulatory exclusivity has expired. The product’s current commercial protection is therefore primarily based on:

• Any unexpired formulation or delivery patents.
• Trade secrets covering manufacturing and fill-finish controls.
• Dental-distribution relationships.
• Brand recognition among periodontists and general dentists.
• Cartridge and applicator supply arrangements.
• Clinical familiarity with the labeled periodontal indication.

The absence of current regulatory exclusivity does not guarantee rapid generic entry. Dental products with specialized delivery systems can have limited market size, higher development costs per unit sold, and more complicated equivalence requirements than conventional tablets or capsules.

How difficult is a generic Oraqix launch?

A generic launch is technically feasible but commercially narrower than a standard oral solid generic.

Regulatory barriers

The main regulatory questions are:

• Whether the product can be submitted through an ANDA.
• Whether the applicator is the same, sufficiently similar, or a combination-product component requiring separate review.
• Whether in vitro studies can establish equivalent drug release and delivery.
• Whether clinical endpoint studies are required.
• Whether the proposed label can match the reference product without patented indications.

The most attractive pathway would preserve the reference product’s qualitative and quantitative excipient profile and use a comparable cartridge and applicator. A materially different polymer system or delivery device would increase development and review risk.

Manufacturing barriers

The product requires specialized control of:

• Viscous liquid processing.
• Active dissolution and uniformity.
• Air entrapment.
• Cartridge filling.
• Applicator fit and leakage.
• Container-closure integrity.
• Long-term stability.
• Microbial quality.

These requirements can deter small generic companies without sterile or semisolid fill-finish capabilities. A contract development and manufacturing organization with cartridge filling and oral semisolid experience could lower entry costs.

Which companies could challenge Oraqix commercially?

The likely competitor groups are:

1. Dental-specialty generic manufacturers.
2. Companies selling lidocaine-prilocaine topical products.
3. Dental device companies with periodontal applicators.
4. Contract manufacturers with semisolid and cartridge capabilities.
5. Local-anesthetic companies seeking dental line extensions.

The strongest commercial challenger would combine a low-cost formulation with an applicator that dentists can use without changing procedure workflow. A product that requires a separate syringe, different tip, or manual dose measurement would face adoption friction even if its active ingredients are identical.

What licensing opportunities exist around Oraqix?

Licensing opportunities are most credible in four areas:

Excipient and formulation licensing

A platform that improves retention, onset, taste, or stability could be licensed to a dental pharmaceutical company. The asset would need comparative data against Oraqix, including viscosity, drug release, local tolerance, and dose delivery.

Device licensing

A low-cost, low-dead-volume cartridge or ergonomic periodontal applicator could support a combination-product licensing model. Device differentiation may be easier to defend than a basic lidocaine-prilocaine composition.

Regional commercialization

Oraqix is particularly suited to regional licensing in markets where periodontal procedures are expanding but injectable dental anesthesia is less convenient. Local partners could provide dental-channel access, reimbursement knowledge, and regulatory support.

Manufacturing licensing

A company with an optimized fill-finish process could license a finished product or supply a private-label version. The economic value would depend on cartridge throughput, yield, stability, and minimum order volumes.

How does Oraqix compare with injectable dental anesthetics?

Factor	Oraqix	Injectable dental anesthetic
Administration	Periodontal pocket application	Injection
Patient experience	No needle	Needle-based
Depth of anesthesia	Localized periodontal anesthesia	Broader and often deeper anesthesia
Procedure fit	Scaling and root planing	Restorative and surgical procedures
Delivery complexity	Cartridge and blunt applicator	Syringe and needle
Commercial differentiation	Delivery convenience	Broader clinical coverage
Main limitation	Restricted indication and localized effect	Injection discomfort and needle aversion

Oraqix is not a complete substitute for injectable anesthesia. Its commercial opportunity is strongest in procedures where injection avoidance has value and deep pulpal or surgical anesthesia is unnecessary.

What is the revenue opportunity for an Oraqix competitor?

The addressable market is constrained by the product’s periodontal indication and specialist distribution model. Revenue potential depends on:

• Number of scaling and root planing procedures.
• Adoption by general dentists and periodontists.
• Price per cartridge.
• Cartridges used per procedure.
• Generic discount relative to the branded product.
• Dental reimbursement and patient payment.
• Distributor margins.
• Geographic launch scope.

A generic could gain share through a 20% to 40% price reduction while preserving dentist workflow. A differentiated formulation could command a premium only if it demonstrates fewer applications, faster procedure time, better patient tolerance, or lower total treatment cost.

What is the commercial outlook for Oraqix?

Oraqix is a niche product with a defensible delivery concept but a limited therapeutic label. The most practical opportunity is a lower-cost, formulation-matched generic supported by a reliable applicator. Higher-value opportunities involve modified release, improved retention, reduced taste, or better device ergonomics.

The strongest development sequence is:

1. Reproduce the reference formulation and delivery performance.
2. Establish a low-cost cartridge and fill-finish process.
3. Map current Orange Book listings and relevant patent claims.
4. Assess ANDA versus 505(b)(2) feasibility.
5. Test a differentiated formulation only after the reference-equivalent product economics are established.
6. Pursue regional dental-distribution partnerships.

Key Takeaways

• Oraqix contains lidocaine 25 mg/g and prilocaine 25 mg/g in a periodontal gel.
• Poloxamer 188 and glycofurol are central to viscosity, solubilization, delivery, and local retention.
• The main commercial moat is the combined formulation, cartridge, applicator, and dental workflow.
• Original regulatory exclusivity is no longer the principal barrier to entry.
• A generic developer’s primary risks are formulation equivalence, device compatibility, cartridge manufacturing, and patent-use analysis.
• The clearest product opportunities are lower-cost generics, improved-retention gels, faster-onset products, and better-tolerated formulations.
• Licensing value is strongest in delivery devices, excipient platforms, regional commercialization, and specialized fill-finish manufacturing.

FAQs

Can Oraqix be reformulated with a different polymer?

Yes. A different polymer could support a design-around or differentiated product, but it could change viscosity, drug release, extrusion force, retention, and local tolerability. Regulatory requirements would depend on the magnitude of the formulation and device changes.

Is Oraqix a candidate for an ANDA?

Potentially. An ANDA is most plausible for a product that matches the reference product’s active ingredients, strength, dosage form, route, excipient profile, delivery system, and labeling. A materially different product may require a 505(b)(2) application.

Does Oraqix require preservatives?

The single-use cartridge presentation can support a preservative-free strategy. Any multi-dose design would face greater microbiological-control requirements and would need a different stability and packaging assessment.

Could a biosimilar compete with Oraqix?

No. Oraqix is a small-molecule lidocaine-prilocaine product, not a biologic. Competition would arise through generic, hybrid, reformulated, or device-enabled products rather than biosimilar pathways.

Which Oraqix improvement is most commercially attractive?

A reference-equivalent generic with a lower-cost cartridge and dependable applicator is the most direct opportunity. A premium product would need clinical evidence showing a meaningful benefit in onset, residence time, taste, repeat dosing, or procedure efficiency.

References

1. U.S. Food and Drug Administration. (2003). Oraqix (lidocaine and prilocaine) periodontal gel, NDA 021645: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. European Medicines Agency. (n.d.). Oraqix: Product information. EMA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2017). ANDA submissions: Product-specific guidances for industry. FDA.